![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Idecabtagene vicleucel为复发性/耐药性多发性骨髓瘤与功能障碍的T细胞治疗提供了仿制性抗原受体T细胞疗法
Surbhi Sidana1, Lauren C Peres2, Hamza Hashmi3
1Stanford University School of Medicine. Surbhi.Sidana@stanford.edu.
Haematologica
|September 21, 2023
概括
用idecabtagene vicleucel (ide-cel) 进行化学抗原受体 (CAR) T细胞治疗对于多发性骨髓瘤患者具有功能障碍 (RI) 是可行的. 安全性和疗效的结果与没有RI的患者相似,除了短期细胞衰竭外,副作用类似.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 复发多发性骨髓瘤 (MM) 患者通常患有功能障碍 (RI).
- 在MMRI患者中,仿真抗原受体 (CAR) T细胞治疗的结果尚未得到充分确立.
- Idecabtagene vicleucel (ide-cel) 是一种用于复发性/耐药性MM的CART细胞疗法.
研究的目的:
- 评估ide-cel在患有复发MM和不同程度功能障碍 (RI) 的患者的安全性和疗效.
- 为了比较具有和没有RI的患者在ide-cel治疗的结果.
主要方法:
- 对214名患有复发MM的患者进行了回顾性分析,这些患者接受了ide-cel治疗.
- 患者根据功能进行分类,由肌素清除率 (CrCl) 定义.
- 严重的RI被定义为CrCl<30毫升/分钟或透析依赖.
主要成果:
- 28名患者 (13%) 患有RI,其中11人患有严重RI.
- 细胞因子释放综合征和免疫效应细胞相关的神经毒性综合征的发生率在两组之间相似.
- 患有RI的患者经历了更高的短期等级≥3细胞衰竭,但长期结果相似.
- 治疗后,功能没有恶化.
- 应答率 (93% vs. 82%) 和无进展生存时间 (9 vs. 8 个月) 是可比的.
结论:
- 在复发性多发性骨髓瘤患者的功能障碍 (RI) 中,idecabtagene vicleucel (ide-cel) 治疗是可行的.
- 在RI患者中,ide-cel的安全性和有效性概况与没有RI的患者相似.
- 在RI患者中观察到较高的短期高度细胞衰竭,但没有影响长期结果.
相关概念视频
01:27Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K